High expression of the transcriptional coactivator TAZ is associated with a worse prognosis and affects cell proliferation in patients with medulloblastoma

Wang,Hao; Zhou,Ji; Yang,Dong; Yi,Liang; Wang,Xuhui; Ou,Yangqing; Yang,Donghong; Xu,Lunshan; Xu,Minhui

doi:10.3892/ol.2019.10851

High expression of the transcriptional coactivator TAZ is associated with a worse prognosis and affects cell proliferation in patients with medulloblastoma

Authors:
- Hao Wang
- Ji Zhou
- Dong Yang
- Liang Yi
- Xuhui Wang
- Yangqing Ou
- Donghong Yang
- Lunshan Xu
- Minhui Xu
View Affiliations

Affiliations: Department of Neurosurgery, Daping Hospital, Third Military Medical University, Chongqing 400042, P.R. China, Department of Neurosurgery, Rocket Force General Hospital, Chinese People's Liberation Army, Beijing 100088, P.R. China, Department of Healthy Management, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing 400042, P.R. China
Published online on: September 11, 2019 https://doi.org/10.3892/ol.2019.10851
Pages: 5591-5599

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The transcriptional coactivator tafazzin (TAZ) serves pivotal roles in organ development, tumor initiation and tumor progression. However, to the best of our knowledge, the expression of TAZ and its clinical significance in human medulloblastoma have not been defined. The present study aimed to clarify the clinical and biological significance of TAZ expression in human medulloblastoma. Immunohistochemical staining for TAZ was performed with 72 medulloblastoma and three normal brain tissue samples. A high expression level of TAZ was detected in 65.28% of medulloblastoma tissues, whereas low expression was identified in the normal brain tissues. TAZ expression was significantly associated with medulloblastoma recurrence. However, the expression of TAZ was not associated with sex, age, tumor location, tumor maximal diameter and tumor histology. Furthermore, both the overall survival and tumor‑free survival rate of patients with high levels of expression of TAZ were shorter compared with those of patients with tumors expressing low levels of TAZ. In univariate and multivariate Cox regression analyses, TAZ expression was identified as a significant prognostic factor for patients with medulloblastoma. Functionally, downregulation of TAZ inhibited the proliferation and tumor formation of medulloblastoma cells and the expression of cell‑cycle associated proteins in Daoy cells. In conclusion, high expression of TAZ may serve as a prognostic marker for patients with medulloblastoma and TAZ may be a potential target for medulloblastoma therapy.

View Figures

View References

1	Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC, Rutkowski S, Ellison DW, Malkin D, Taylor MD, et al: Medulloblastoma. Nat Rev Dis Primers. 5:112019. View Article : Google Scholar : PubMed/NCBI
2	Ris MD, Walsh K, Wallace D, Armstrong FD, Holmes E, Gajjar A, Zhou T and Packer RJ: Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average-risk medulloblastoma: COG A9961. Pediatr Blood Cancer. 60:1350–1357. 2013. View Article : Google Scholar : PubMed/NCBI
3	Moxon-Emre I, Bouffet E, Taylor MD, Laperriere N, Scantlebury N, Law N, Spiegler BJ, Malkin D, Janzen L and Mabbott D: Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. J Clin Oncol. 32:1760–1768. 2014. View Article : Google Scholar : PubMed/NCBI
4	Polkinghorn WR and Tarbell NJ: Medulloblastoma: Tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol. 4:295–304. 2007. View Article : Google Scholar : PubMed/NCBI
5	Saha A, Salley CG, Saigal P, Rolnitzky L, Goldberg J, Scott S, Olshefski R, Hukin J, Sands SA, Finlay J and Gardner SL: Late effects in survivors of childhood CNS tumors treated on Head Start I and II protocols. Pediatr Blood Cancer. 61:1644–1652; quiz 1653–1672. 2014. View Article : Google Scholar : PubMed/NCBI
6	Wang J, Garancher A, Ramaswamy V and Wechsler-Reya RJ: Medulloblastoma: From molecular subgroups to molecular targeted therapies. Annu Rev Neurosci. 41:207–232. 2018. View Article : Google Scholar : PubMed/NCBI
7	Liu KW, Pajtler KW, Worst BC, Pfister SM and Wechsler-Reya RJ: Molecular mechanisms and therapeutic targets in pediatric brain tumors. Sci Signal. 10:2017. View Article : Google Scholar
8	Robinson GW, Witt H and Resnick A: Exploiting laboratory insights to improve outcomes of pediatric central nervous system tumors. Am Soc Clin Oncol Educ Book. 35:e540–e546. 2016. View Article : Google Scholar : PubMed/NCBI
9	Tamayo P, Cho YJ, Tsherniak A, Greulich H, Ambrogio L, Schouten-van Meeteren N, Zhou T, Buxton A, Kool M, Meyerson M, et al: Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol. 29:1415–1423. 2011. View Article : Google Scholar : PubMed/NCBI
10	von Bueren AO, Kortmann RD, von Hoff K, Friedrich C, Mynarek M, Müller K, Goschzik T, Zur Mühlen A, Gerber N, Warmuth-Metz M, et al: Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters. J Clin Oncol. 34:4151–4160. 2016. View Article : Google Scholar : PubMed/NCBI
11	Yu FX, Zhao B and Guan KL: Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 163:811–828. 2015. View Article : Google Scholar : PubMed/NCBI
12	Moroishi T, Park HW, Qin B, Chen Q, Meng Z, Plouffe SW, Taniguchi K, Yu FX, Karin M, Pan D and Guan KL: A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis. Genes Dev. 29:1271–1284. 2015. View Article : Google Scholar : PubMed/NCBI
13	Totaro A, Panciera T and Piccolo S: YAP/TAZ upstream signals and downstream responses. Nat Cell Biol. 20:888–899. 2018. View Article : Google Scholar : PubMed/NCBI
14	Maugeri-Saccà M and De Maria R: The Hippo pathway in normal development and cancer. Pharmacol Ther. 186:60–72. 2018. View Article : Google Scholar : PubMed/NCBI
15	Murakami M, Nakagawa M, Olson EN and Nakagawa O: A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc Natl Acad Sci USA. 102:18034–18039. 2005. View Article : Google Scholar : PubMed/NCBI
16	Di Palma T, D'Andrea B, Liguori GL, Liguoro A, de Cristofaro T, Del Prete D, Pappalardo A, Mascia A and Zannini M: TAZ is a coactivator for Pax8 and TTF-1, two transcription factors involved in thyroid differentiation. Exp Cell Res. 315:162–175. 2009. View Article : Google Scholar : PubMed/NCBI
17	Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY and Guan KL: TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem. 284:13355–13362. 2009. View Article : Google Scholar : PubMed/NCBI
18	Zhang X, Zhao H, Li Y, Xia D, Yang L, Ma Y and Li H: The role of YAP/TAZ activity in cancer metabolic reprogramming. Mol Cancer. 17:1342018. View Article : Google Scholar : PubMed/NCBI
19	Liu H, Du S, Lei T, Wang H, He X, Tong R and Wang Y: Multifaceted regulation and functions of YAP/TAZ in tumors (Review). Oncol Rep. 40:16–28. 2018.PubMed/NCBI
20	Choi W, Kim J, Park J, Lee DH, Hwang D, Kim JH, Ashktorab H, Smoot D, Kim SY, Choi C, et al: YAP/TAZ initiates gastric tumorigenesis via upregulation of MYC. Cancer Res. 78:3306–3320. 2018.PubMed/NCBI
21	Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, et al: The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 147:759–772. 2011. View Article : Google Scholar : PubMed/NCBI
22	Cassia GSE, Alves C, Taranath A, López NS, Oztekin O, Gonçalves FG and Patay Z: Childhood medulloblastoma revisited. Top Magn Reson Imaging. 27:479–502. 2018. View Article : Google Scholar : PubMed/NCBI
23	Rutkowski S, von Hoff K, Emser A, Zwiener I, Pietsch T, Figarella-Branger D, Giangaspero F, Ellison DW, Garre ML, Biassoni V, et al: Survival and prognostic factors of early childhood medulloblastoma: An international meta-analysis. J Clin Oncol. 28:4961–4968. 2010. View Article : Google Scholar : PubMed/NCBI
24	Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, et al: Risk stratification of childhood medulloblastoma in the molecular era: The current consensus. Acta Neuropathol. 131:821–831. 2016. View Article : Google Scholar : PubMed/NCBI
25	Low JA and de Sauvage FJ: Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol. 28:5321–5326. 2010. View Article : Google Scholar : PubMed/NCBI
26	Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, et al: Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 29:1408–1414. 2011. View Article : Google Scholar : PubMed/NCBI
27	Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, Cho YJ, Koster J, Schouten-van Meeteren A, van Vuurden D, et al: Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 123:473–484. 2012. View Article : Google Scholar : PubMed/NCBI
28	Łastowska M, Trubicka J, Niemira M, Paczkowska-Abdulsalam M, Karkucińska-Więckowska A, Kaleta M, Drogosiewicz M, Tarasińska M, Perek-Polnik M, Krętowski A, et al: ALK expression is a novel marker for the WNT-activated type of pediatric medulloblastoma and an indicator of good prognosis for patients. Am J Surg Pathol. 41:781–787. 2017. View Article : Google Scholar : PubMed/NCBI
29	Takei H, Bhattacharjee MB, Rivera A, Dancer Y and Powell SZ: New immunohistochemical markers in the evaluation of central nervous system tumors: A review of 7 selected adult and pediatric brain tumors. Arch Pathol Lab Med. 131:234–241. 2007.PubMed/NCBI
30	Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, et al: Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 29:1424–1430. 2011. View Article : Google Scholar : PubMed/NCBI
31	Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, Neben K, Fiegler H, Carter NP, Reifenberger G, et al: Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol. 23:8853–8862. 2005. View Article : Google Scholar : PubMed/NCBI
32	Sun L, Chen F, Shi W, Qi L, Zhao Z and Zhang J: Prognostic impact of TAZ and β-catenin expression in adenocarcinoma of the esophagogastric junction. Diagn Pathol. 9:1252014. View Article : Google Scholar : PubMed/NCBI
33	Wang Z, Liu P, Zhou X, Wang T, Feng X, Sun YP, Xiong Y, Yuan HX and Guan KL: Endothelin promotes colorectal tumorigenesis by activating YAP/TAZ. Cancer Res. 77:2413–2423. 2017. View Article : Google Scholar : PubMed/NCBI